^
CANCER:
Gastrointestinal Cancer
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive
:
A1
FDA - 2d
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive
:
A1
FDA - 2d
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive
:
A2
Servier Press Release - 2d
HER-2 positive
CRC
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
Lancet Oncol - 3d
HER-2 positive
Gastric Cancer
RC48
Sensitive
:
C3
Gastric Cancer - 3d
No biomarker
CRC
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 1wk
HER-2 overexpression + PTEN deletion
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Resistant
:
C3
Sci Rep - 1wk
dMMR/MSI-H + TMB-L
Pancreatic Cancer
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
dMMR/MSI-H + TMB-L
Cholangiocarcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
dMMR/MSI-H + TMB-L
CRC
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
dMMR/MSI-H + TMB-L
Gastric Cancer
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
Pancreatic Cancer
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
Cholangiocarcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
CRC
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
Gastric Cancer
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
Small Intestinal Carcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
dMMR/MSI-H + TMB-L
Small Intestinal Carcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
HER-2 1899‐1G>A
Gastric Adenocarcinoma
trastuzumab
Resistant
:
C4
The Oncologist - 1wk
FGFR2b overexpression + HER2 negative
Gastric Cancer
FPA-144
Sensitive
:
B
Amgen Press Release - 2wk
FGFR2b overexpression + HER2 negative
Gastroesophageal Junction Adenocarcinoma
FPA-144
Sensitive
:
B
Amgen Press Release - 2wk
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive
:
A2
Clin Cancer Res - 2wk
BRCA1 S451Lfs*20
Gallbladder Cancer
olaparib
Sensitive
:
C4
Onco Targets Ther - 2wk
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
FDA - 3wk
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
A1
FDA - 3wk
No biomarker
Gastric Cancer
nivolumab
Sensitive
:
A1
FDA - 3wk
KRAS mutation
CRC
bevacizumab + PCM-075
Sensitive
:
C2
Cardiff Oncology Press Release - 3wk
HER-2 amplification
Esophageal Adenocarcinoma
trastuzumab + avelumab
Sensitive
:
C2
AACR 2021 - 3wk
HER-2 amplification
Gastric Adenocarcinoma
trastuzumab + avelumab
Sensitive
:
C2
AACR 2021 - 3wk
MET amplification
Gastric Adenocarcinoma
crizotinib
Sensitive
:
C3
Target Oncol - 3wk
MET amplification
GastroEsophageal Cancer
crizotinib
Sensitive
:
C3
Target Oncol - 3wk
KRAS G13D
CRC
bevacizumab + PCM-075
Sensitive
:
C3
Cardiff Oncology Press Release - 3wk
KRAS G12V
CRC
bevacizumab + PCM-075
Sensitive
:
C3
Cardiff Oncology Press Release - 3wk
KRAS G12D
CRC
bevacizumab + PCM-075
Sensitive
:
C3
Cardiff Oncology Press Release - 3wk
ASS1 negative
HCC
BCT-100
Sensitive
:
C3
Invest New Drugs - 3wk
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
CRC
pembrolizumab
Sensitive
:
C4
Onco Targets Ther - 3wk
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive
:
A1
No biomarker
HCC
pembrolizumab
Sensitive
:
A1
No biomarker
HCC
bevacizumab + atezolizumab
Sensitive
:
A1
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive
:
A1
MSI-H/dMMR
CRC
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
CRC
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Gastric Cancer
TPF
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive
:
A1
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
BRAF V600E
CRC
cetuximab + binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
CRC
cetuximab + encorafenib
Sensitive
:
A1
No biomarker
Colon Cancer
capecitabine
Sensitive
:
A1
No biomarker
Rectal Cancer
FOLFIRI
Sensitive
:
A1
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Gastric Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
CRC
bevacizumab
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our